| NOTE 5:- |
CONTINGENT LIABILITIES AND COMMITMENTS |
According to the patent license agreement
that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes
of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain
territories.
The Company is committed to pay royalties
as follows:
|
a. |
A one-time concession commission of €25 thousand; |
|
b. |
Annual royalties of €10 thousand until the clinical trials commence; |
|
c. |
2%-3% of net sales (as defined in the agreement) received by the Company; |
|
d. |
Royalties in a total amount of up to €850 thousand based on certain progress milestones in the
license stages of the products, which are the subject of the patent under the agreement, as follows: (i) €50 thousand upon initiation
of Phase I studies; (ii) €100 thousand upon initiation of Phase II studies; (iii) €200 thousand upon initiation of Phase III
studies; and (iv) €500 thousand upon marketing approval by any regulatory authority. |
|
e. |
If the agreement is sublicensed to another company, the Company will provide Leiden University royalties
at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as
discussed in this paragraph. |
As of June 30, 2025 and December 31,
2024, no material accrual has been recorded with respect to Leiden University.
|